

## DAFTAR PUSTAKA

- Bartlett, D.,L., Bisceglie, A.,M., Dawson, L., A. 2008. Cancer of the liver. *dalam: I. DeVita, T. Vincent, S. Theodore, A. Steven (editors). Cancer: Principles and practice of oncology.* Lippincott Williams & Wilkins. USA: 1129-1156
- Bruix, J., and Sherman, M. 2010. AASLD Practice Guideline: management of hepatocellular carcinoma: an update. *Hepatology.* 53(3):1020-1022
- Bertino, G., Demma, S., Bertino, N., Ardiri, A. 2014. Management of Hepatocellular Carcinoma: An Update at the Start of 2014. *J Gastroint Dig Syst.* 4:178
- Budihusodo, U. 2014. Karsinoma Hati. *dalam: S. Setiati, I. Alwi, A.W. Sudoyo, M. Simadibrata, B. Setiyohadi, A.F. Syam (editors). Buku Ajar Ilmu Penyakit Dalam.* Jilid I. Edisi VI. Internal Publishing. Pusat Informasi dan Penerbitan Departemen Ilmu Penyakit Dalam FKUI. 3040-3046
- Carr, B. 2012. Tumors of the liver and biliary tree. *dalam: D.L. Longo, A.S. Fauci, C.A. Langford (editors). Harrison's Gastroenterology and Hepatology.* McGraw-Hill Companies. USA:517-527
- Cheng, H., Chang, Y., Chen, Y., Lee, T., Tai, D., Lin, D. 2007. AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein. *J Chin Med Assoc.* 70(8):310-317
- Chen, G., Ho, R., Wong, J., Lee, K., Lay, P. 2007. Single nucleotide polymorphism in the promoter region human-alpha phetoprotein (AFP) gene and its significant in hepatocellular carcinoma. *EJSO* 33: 882-886
- Debruyne, E.,N and Delanghe, J.,R. 2008. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. *Clin Chim Acta.* 395: 19-26
- Departemen Kesehatan R.I. 2005. Rencana Strategi Departemen Kesehatan. Jakarta: Depkes RI
- Florman, S., Miller CM. 2006. Liver Donor Liver Transplantation. *Liver Transpl.* 12: 499 - 510
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., *et al.*, 2015. Cancer incidence and mortality worldwide, sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer,* 136(5): E359-86.
- Fox, R., Berhane, S., Teng, M., Cox, T., Tada, T., Toyoda, H. 2014. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. *British Journal of Cancer.* 110;2090-2098

- Giannelli, G., Marinosci, F., Sgarra, C., Lupo, L., Dentico, P., Antonaci S. 2005. Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. *Int J Cancer*. 116: 579-583
- Greten, TF, Papendorf, F., Bleck, J.F.. 2005. Survival rate in patient with hepatocellular carcinoma:a retrospective analysis of 389 patients. *British Journal of Cancer*. 92: 1862-1868.
- Hadziyannis, E., Sialevris, K., Georgiou, A., Koskinas, J. 2013. Analysis of serum  $\alpha$ -fetoprotein-L3% and des- $\gamma$  carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total  $\alpha$ -fetoprotein levels. *Oncology Reports*. 29:835-839
- Hayashi, K., Kumada, T., Nakano, S., Takeda, I., Sugiyama, K., Kiriyama, S., et al. 1999. Usefulness of measurement of Lens Culinaris Agglutinin-reactive fraction of  $\alpha$ -fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. *Am J Gastroenterol*. 94(10):3028-3033
- Huang, T., Shyu, Y., Turner, R., Chen, H., Chen, P. 2013. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. *Biomed Central*. 2:37
- Jelic, S., Sotiropoulos, G., C. 2010. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 20(4):41-45
- Johnson, P. 2002. Tumor Markers in Primary Maliganncies of The Liver. *dalam: Diamandis, E.P., Fritsche, H.,A., Lilja, H., Chan, D.,W., Schwartz, M.,K (editors). Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications. Am Assoc Clin Chem*. 269-279
- Kamath, P.S., Kim, W.R. 2007. Advance Liver Disease Study Group. The Model for End Stage Liver Disease (MELD). *Hepatology*. Mar;45(3): 797 -805.
- Keefe E., B. 2001. Liver Transplantation: Current Status and Novel Approaches to Liver Replacement. *Gastroenterology*. 120: 749 - 762
- Kim W.R., Biggins, S.W., Kremers, W.K. Wiesner, R.H., Kamath, P., S., Benson, J.T., Edwards, E., Therneau T.M. 2008. Hyponatremia and Mortality among patients on the liver-transplant waiting list. *N Engl J Med*. Sep 4;359(10): 1018 - 26
- Kinoshita, A., Onoda, H., Fushiya, N., Koike, K., Nishino, H., Tajiri, H. 2015. Staging systems for hepatocellular carcinoma: Current status and future perspectives. *World J Hepato*. 7(3):406-424

- Kumada, T., Toyoda, H., Tada, T., Kiriya, S., Tanikawa, M., Hisanaga, Y., et al. 2014. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. *Japan Soc Gastroenterol.* 49:555-563
- Lavanchy, D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepatitis.* 11:97-107
- Leerapun, A., Suravarapu, S., V., Bida, J., P., et al. 2007. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. *Clin Gastroenterol Hepatol.* 5: 394-402
- Li, D., Mallory, T., Satomura, S. 2001. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. *Clin Chim Acta.* 313:5-19
- Marrero, J.A., Fontana, R.J., Barrat, A. et al. 2005. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. *Hepatology.* 2005 Apr. 41(4): 707 - 16
- Mittal, S., El-Serag, H., B. 2013. Epidemiology of HCC: Consider the Population. *J. clin Gastroenterol.* 47(0):S2-S6
- Morimoto, M., Numata, K., Nozaki, A., Kondo, M., Moriya, S., Taguri, M., et al. 2012. Novel Lens culinaris agglutinin-reactive fraction of  $\alpha$ -fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low  $\alpha$ -fetoprotein concentrations. *Int J Clin Oncol.* 17:373-379
- Nakamura, S., Nouse, K., Sakaguchi, K., et al. 2006. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. *Am J Gastroenterol.* 101: 2038-2043
- Parkin, D., M., Bray, F., Ferlay, J., et al. 2001. Estimating the world cancer burden: GLOBOCAN 2000. *Int J Cancer.* 94:153-156
- Pawlik, T.M., Delman, K.A., Vauthey, J. N. 2005. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. *Liver Transpl. Sep.* 11(9): 1086 - 92.
- Ryder, S.D. 2003. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. *Gut.* 52
- Schwartz, M.J. 2009. Clinical features and diagnosis of primary hepatocellular carcinoma. UpTo date version 21.2

- Seeff, L., B., Hoofnagle, J., H. 2006. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. *Oncogene*. 25:3771-3777
- Shi, Y., Chen, J., Li, L., *et al.* 2011. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. *Technol Cancer Res Treat*. 10:287-294
- Siregar, G.A., 2011. Penatalaksanaan non bedah dari karsinoma hati. *Universa Medicina*. 24 (1):35-42.
- Shirakawa, H., Kumnuma, T., Nishimura, Y., *et al.* 2009. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. *Int J Oncol*. 34: 649-656
- Singhal, A., Jayaraman, M., Dhanasekaran, D.,N., Kohli, V. 2012. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. *Crit Rev Oncol Hematol*. 82: 116-140
- Suriapranata, I.,M., Sudania, W.,M., Tjong, W.,Y., Suciptan, A.,A., Gani, R.,A., Hasan, I., *et al.* 2010. Alpha-feto-protein gene polymorphisms and risk of HCC and cirrhosis. *Clinica Chimica Acta*. 411:351-358
- Thorgeirsson, S.S., Grisham, J.W. 2002. Molecular Pathogenesis of Human Hepatocellular Carcinoma. *Nat Geneat*. Aug. 31(4):339 -46
- Toyoda, H., Kumada, T., Tada, T., Kaneoka, Y., Maeda, A., Kanke, F., Satomura, S. 2011. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20ng/mL. *Japan Cancer Assoc*.102(5);1025-1031
- Tremosini, S., Forner, A., Boix, L. 2012. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. *Gut*. 61:1481-1487
- Venook, A.,P., Papandreou, C., Guevara, L. 2010. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. *The oncologist*. 15:5-13
- Waghray, A., Murali, A.,R., Menon, K.,V. 2015. Hepatocellular carcinoma: from diagnosis to treatment. *World J Hepatol*. 7(8):1020-1029
- Wang, F., Geng, Y., Zhang, W.,M., Geng, X. 2012. Identification of ZAG protein as a novel serologic biomarker candidate for liver cancer. *Adv Mater Res*. 340:383-389

- Wong, R., and Corley, D.,A. 2008. Racial and ethnic variations in hepatocellular carcinoma incidence within the Unites States. *Am J Med.* 121:525-531
- Wong, V., W., Chim, A., M., Wong, G., L., Sung, J., J., Chan, H., L. 2007. Performance of the new MELD-Na Score in predicting 3-Month and 1-year Mortality in Chinese patients with chronic hepatitis B. *Liver Transplantation.* 13: 1228 - 1235.
- Yamamoto, Y., Kosaka, N., Tanaka, M. 2009. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. *Biomarkers.* 14: 529-538
- Yi, X., Yu, S., Bao, Y. 2013. Alpha-fetoprotein-L3 in hepatocellular carcinoma: A meta-analysis. *Clinica Chimica Acta.* 425:212-220
- Zhang, Y., Deng, Z.,S., Liao, M.,M., Wang, N., Zhang, X.,Q., Yu, H.,Y., Zhang, Y.,D. 2012. Tumor associated glycoprotein-72 is a novel marker for poor survival in hepatocellular carcinoma. *Pathol Oncol Res.* 18:911-916
- Zhang, L., Wang, J.,N., Tang, J.,M. 2012. VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. *Mol Biol Rep.* 39:5085-5093
- Zhao, Y., Ju, Q., Li, G. 2013. Tumor markers for hepatocellular carcinoma (review). *Mol Clin Oncol.* 1:593-598